Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 9, 2026 · Material agreement · Investor press release · Financial statements
| ItemItem | Disclosure |
|---|---|
| Item 1.01 | Entered a material definitive agreement |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Nuvalent, Inc. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
1 Stock-exchange announcement For media and investors only Issued: 9 June 2026, London UK GSK enters agreement to acquire Nuvalent, Inc. Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies Includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer (NSCLC), currently under US FDA review for 2026 approvals Accelerates entry into lung cancer, pr…
This filing reports Item 1.01 (entered a material definitive agreement). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Nuvalent, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
